CD&R, Merck GHI and McKesson Ventures Recapitalize M2GEN
March 17, 2021
Clayton, Dubilier & Rice (CD&R) led a recapitalization of oncology data and informatics company M2GEN, with strategic investments from Merck Global Health Innovation Fund and McKesson Ventures. The transaction — which closed with terms undisclosed — positions CD&R as the largest shareholder and will fund growth of M2GEN's linked clinical and genomic data assets and expanded technology and informatics capabilities.
- Buyers
- Clayton, Dubilier & Rice (CD&R), Merck Global Health Innovation Fund (Merck GHI), McKesson Ventures
- Targets
- M2GEN
- Industry
- Healthcare Services
- Location
- Florida, United States
- Transaction Type
- Recapitalization
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.